Celecoxib Prostate Cancer

Celecoxib Shows Promise Against Recurrent Prostate Cancer

In an early report, the drug decreased or stabilized prostate-specific antigen levels. Oct. 12, 2004 (New Orleans) — The cyclooxygenase-2 (COX-2) inhibitor celecoxib.

Celebrex Provides A Two Pronged Attack Against Prostate Cancer

18, 2005) — PHILADELPHIA -- Celecoxib, a selective COX-2 inhibitor with promising anti-cancer properties, has now been found to attack prostate cancer cells.

Phase II Trial of Celecoxib in Prostate-Specific Antigen Recurrent

This study evaluated the efficacy of the COX-2 inhibitor celecoxib in prostate-specific antigen (PSA) recurrent prostate cancer after radiation therapy.

Celecoxib Versus Placebo for Men With Prostate Cancer and a Rising

PURPOSE: To assess the biologic activity of celecoxib, a selective cyclooxygenase-2 inhibitor, in men with recurrent prostate cancer using change in.

Celecoxib Inhibits Prostate Cancer Growth: Evidence of a

Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent Mechanism Manish I. Patel 1 ,2 ,5 , Kotha Subbaramaiah 1 , Baoheng Du 1 , Mindy Chang 1.

Hormone therapy with zoledronic acid, docetaxel or celecoxib for

Hormone therapy is often used to treat prostate cancer[LINK menu 2657] that has spread outside the prostate gland. It can work very well, but the cancer often starts to grow again.

Celecoxib Shows Promise Against Recurrent Prostate Cancer

In an early report, the drug decreased or stabilized prostate-specific antigen levels.

News - Celecoxib (Celebrex) May Foil Recurrent Prostate Cancer

Celecoxib (Celebrex) May Foil Recurrent Prostate Cancer: Presented at ACS.

National Prostate Cancer Coalition: Green Tea and COX-2 Inhibitors

The researchers repeated the experiment in mouse models of prostate cancer, using celecoxib and an oral suspension of the decaffeinated green tea polyphenol.

Research into treatments for prostate cancer

A trial called STAMPEDE is studying the combination of hormone therapy with chemotherapy, bisphosphonates or celecoxib for men who have prostate cancer that.

Celecoxib Inhibits Prostate Cancer Growth: Evidence of a

Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent Mechanism. Manish I. Patel1,2,5, Kotha Subbaramaiah1, Baoheng Du1.

Celecoxib in Treating Patients With Relapsed Prostate Cancer Following

Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy This study is ongoing, but not recruiting participants.

Clinical Trials (PDQ®) - National Cancer Institute

Phase II Study of Celecoxib in Patients With Prostate Cancer in Biochemical Relapse After Prior Definitive Radiotherapy or Radical Prostatectomy.

OHSU Cancer Institute - Cancer Treatment and Information

Cancer Treatment and general Cancer Information from the OHSU Cancer Institute. Learn about Breast Cancer, prostate Cancer, and more.

Celecoxib inhibits prostate cancer growth: evidence of a

Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. journal article. via NIH Pubmed; has authors. Dannenberg, Andrew J. | Henry R.

Prostate Cancer and Prostatic Diseases - Inhibition of Akt pathways in

Chen KF, Lai JP, Tseng PH et al . 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer.

Weekly administration of docetaxel in combination with

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final.

Phase II Trial of Celecoxib in Prostate-Specific Antigen Recurrent

This study evaluated the efficacy of the COX-2 inhibitor celecoxib in prostate-specific antigen (PSA) recurrent prostate cancer after radiation therapy.

Celecoxib Inhibits Prostate Cancer Growth: Evidence of a

Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent Mechanism Manish I. Patel 1 ,2 ,5 , Kotha Subbaramaiah 1 , Baoheng Du 1 , Mindy Chang 1.

News - ACS: Celecoxib (Bextra) May Foil Recurrent Prostate Cancer

ACS: Celecoxib (Bextra) May Foil Recurrent Prostate Cancer.